Apellis Pharmaceuticals, Inc. APLS NASDAQ

Apellis Pharmaceuticals, Inc. (APLS) reported exceptional year-over-year revenue growth of +28.5% through 2025-12 (TTM revenue vs prior-year TTM). The latest quarter net income was –$59M, with a YoY change of +111.3%. The net profit margin is -29.5%, which is negative. the company was profitable in 1 out of the last 4 quarters. The gross margin is 87.8% (high), up 2.8pp vs the prior year. With a $5B market cap, MOAT composite score of 74/100 (strong competitive position).

Criteria proven by this page:

• GROWTH (100/100, Pass) — proving strong growth momentum
• PAST (25/100, Fail) — the company has frequently reported losses. Looking at the full 13-year annual history, the company was profitable in 1 of 13 years — a mixed long-term record
• INCOME (30/100, Fail) — the company is currently operating at a loss
• MOAT (74/100, Pass) — strong gross margins and market scale prove a durable competitive advantage

Overall SharesGrow Score: 48/100 with 1/7 criteria passed.